Skip to content
PubMed This is a summary of 9 peer-reviewed journal articles Updated
Neurology · Parkinson Disease 25 (PARK25), Autosomal Recessive, With Impaired Intellectual Development

The Science of PARK25: The PPP2R4 Gene

At a Glance

PARK25 is a rare inherited condition linked to changes in both copies of the PPP2R4 gene. It can cause early-onset parkinsonism and intellectual disability, and diagnosis requires a genetics specialist to interpret pathogenic or likely pathogenic variants with the clinical picture.

While the symptoms of PARK25 are physical and cognitive, the root of the condition lies deep within the cells of the brain. Understanding the biology of PARK25 helps explain why the body behaves the way it does and why a precise genetic diagnosis is the only way to distinguish it from other similar conditions.

The PPP2R4 Gene and the PP2A Enzyme

PARK25 is associated with variants in the PPP2R4 gene (formerly and also known as PTPA) [1]. This gene’s primary job is to provide instructions for making a protein that acts as an “activator” for an essential enzyme called PP2A (protein phosphatase 2A) [1].

Think of the PP2A enzyme as a specialized worker that maintains the health of brain cells by regulating other proteins. However, this worker cannot start its job without a specific “key”—the PPP2R4 protein. In PARK25, the “key” is broken or missing:

  • Reduced Stability: Mutations can make the protein unstable, meaning the body destroys it too quickly [1][2].
  • Impaired Regulation: Without enough functional protein, it may alter PP2A regulation and neuronal signaling; the exact downstream mechanism remains under study [1].
  • Cellular Stress: This altered regulation is hypothesized to eventually lead to the dysfunction of the brain cells that control movement (nigrostriatal neurons) [1].

Autosomal Recessive Inheritance

PARK25 follows an autosomal recessive inheritance pattern. This means a person must have biallelic variants—meaning both copies of their PPP2R4 gene (one from each parent) are mutated—to develop the condition [1][2].

  • Homozygous: Most patients identified so far have the exact same mutation on both copies of the gene [1].
  • Carriers: Parents typically carry only one mutated copy. They are called “carriers” and generally do not show any symptoms of PARK25 [2].

Why Genetic Testing is Crucial

Because PARK25 is ultra-rare and shares symptoms with several other conditions, doctors cannot diagnose it by symptoms alone. Genetic sequencing (such as an Exome or a Parkinson’s Gene Panel) is required to tell PARK25 apart from “look-alike” disorders:

Condition Distinguishing Features
PARK25 (PPP2R4) Juvenile-onset parkinsonism + stable intellectual disability [1].
Wilson Disease Caused by copper buildup. Requires complex clinical and lab evaluation to rule out, not just a gene panel [3][4].
SYNJ1-Related Often involves seizures in childhood before parkinsonism begins [5].
VPS13C-Related May have a more rapid decline in cognitive abilities [6][7].
PTRHD1-Related May include spasticity (unusual muscle tightness) alongside parkinsonism [8].

(Note: This table is illustrative, not diagnostic. These disorders can overlap, and absence of one listed feature does not rule one out. Test interpretation must be individualized).

In some scientific papers, you may see references to “park25” in fruit flies (Drosophila). It is important to know that in flies, “park25” refers to a mutation in the Parkin gene, which is a different human condition (PARK2). Human PARK25 is strictly related to the PPP2R4/PTPA gene [9].

Your Genetic Report Checklist

When you review the genetic test results with a specialist, ensure the following details are present to confirm a PARK25 diagnosis:

  • [ ] Gene Name: Clearly identifies PPP2R4 or PTPA.
  • [ ] Variant Details: Lists the specific “typo,” such as p.Met298Arg, p.Ala171Asp, or p.Met329Val [1][2].
  • [ ] Zygosity and Phase: Confirms the mutations are homozygous (two identical copies) or compound heterozygous (two different mutations, proven to be “in trans” on opposite copies of the gene).
  • [ ] Classification: Labels the variants as Pathogenic or Likely Pathogenic.
  • [ ] VUS Note: A “Variant of Uncertain Significance” (VUS) does not confirm PARK25 and should not be used by itself to guide treatment. Interpretation requires a genetics professional, and family testing may sometimes help reclassify it over time [2].

Common questions in this guide

What gene is associated with PARK25?
PARK25 is associated with variants in the PPP2R4 gene, which was formerly called PTPA. The gene helps make a protein that activates PP2A, an enzyme involved in regulating proteins in brain cells.
How is PARK25 inherited?
PARK25 follows an autosomal recessive pattern, so a person generally needs an altered PPP2R4 copy from each parent to develop the condition. People with one altered copy are carriers and typically do not have PARK25 symptoms.
What genetic test is used to diagnose PARK25?
Exome sequencing or a Parkinson disease gene panel may identify the PPP2R4 variants linked to PARK25. A specialist must confirm that both gene copies carry pathogenic or likely pathogenic variants and interpret the result alongside the person's parkinsonism and intellectual disability.
Does a variant of uncertain significance confirm PARK25?
No. A variant of uncertain significance, or VUS, does not by itself confirm PARK25 and should not be used alone to guide treatment. A genetics professional may recommend family testing or later review as scientific knowledge changes.
What do homozygous and compound heterozygous mean on a PARK25 report?
Homozygous means the same PPP2R4 variant is present on both gene copies. Compound heterozygous means two different variants are present, one on each copy, and testing should establish that they are in trans, or on opposite copies.
Can a Parkinson disease gene panel rule out Wilson disease?
No. Wilson disease is related to copper buildup and requires its own clinical and laboratory evaluation. A gene panel used for PARK25 should not be treated as the only way to rule Wilson disease in or out.
What details should I look for in a PARK25 genetic report?
The report should identify PPP2R4 or PTPA, list the specific variant notation, and state the variants' classification, zygosity, and phase. A diagnosis is generally supported by pathogenic or likely pathogenic variants in both gene copies, while a VUS alone is not confirmatory.

Get notified when new evidence is published on Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (9)
  1. 1

    PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.

    Fevga C, Tesson C, Carreras Mascaro A, et al.

    Brain : a journal of neurology 2023; (146(4)):1496-1510 doi:10.1093/brain/awac326.

    PMID: 36073231
  2. 2

    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.

    Li C, Lin J, Jiang Q, et al.

    Movement disorders : official journal of the Movement Disorder Society 2023; (38(6)):1099-1104 doi:10.1002/mds.29411.

    PMID: 37046398
  3. 3

    Diagnostic challenges and mimicking disorders of Wilson's Disease: A comprehensive review.

    Hashemi SS, Gholoobi A, Naghipoor K, Hamzehloei T

    Caspian journal of internal medicine 2026; (17(2)):229-241 doi:10.22088/cjim.17.2.229.

    PMID: 42668699
  4. 4

    A Case of Megaspleen With Micrographism.

    Bansal S, Tandi R, Sahu S, et al.

    Cureus 2022; (14(9)):e29270 doi:10.7759/cureus.29270.

    PMID: 36277582
  5. 5

    Clinical Variability of SYNJ1-Associated Early-Onset Parkinsonism.

    Lesage S, Mangone G, Tesson C, et al.

    Frontiers in neurology 2021; (12()):648457 doi:10.3389/fneur.2021.648457.

    PMID: 33841314
  6. 6

    Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.

    Lesage S, Drouet V, Majounie E, et al.

    American journal of human genetics 2016; (98(3)):500-513 doi:10.1016/j.ajhg.2016.01.014.

    PMID: 26942284
  7. 7

    Two novel variants of VPS13C gene related Parkinsonism: A case report and literature review.

    Jiang Y, Fan C

    Medicine 2026; (105(2)):e47063 doi:10.1097/MD.0000000000047063.

    PMID: 41517720
  8. 8

    PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability.

    Kuipers DJS, Carr J, Bardien S, et al.

    Movement disorders : official journal of the Movement Disorder Society 2018; (33(11)):1814-1819 doi:10.1002/mds.27501.

    PMID: 30398675
  9. 9

    An altered microbiome in a Parkinson's disease model Drosophila melanogaster has a negative effect on development.

    Parker-Character J, Hager DR, Call TB, et al.

    Scientific reports 2021; (11(1)):23635 doi:10.1038/s41598-021-02624-1.

    PMID: 34880269

This page explains the PPP2R4 gene and PARK25 inheritance for informational purposes only and does not constitute medical advice or a diagnosis. A medical geneticist or genetic counselor should interpret your variants, VUS results, and family-testing options.